Geneva Capital Management LLC Acquires 10,908 Shares of Repligen Co. (NASDAQ:RGEN)

Geneva Capital Management LLC lifted its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 8.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 138,677 shares of the biotechnology company's stock after purchasing an additional 10,908 shares during the quarter. Geneva Capital Management LLC owned about 0.25% of Repligen worth $20,638,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in RGEN. Andra AP fonden bought a new position in shares of Repligen in the second quarter worth $25,000. International Assets Investment Management LLC bought a new position in Repligen in the second quarter valued at $33,000. UMB Bank n.a. increased its stake in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 130 shares during the last quarter. Lazard Asset Management LLC increased its stake in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 136 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 127 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Insiders Place Their Bets

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm's stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company began coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target for the company. UBS Group cut their price target on shares of Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Stephens restated an "overweight" rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Finally, Benchmark restated a "hold" rating on shares of Repligen in a research report on Monday, August 5th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $190.25.

Repligen Price Performance

Shares of Repligen stock traded up $4.03 during trading on Wednesday, reaching $152.62. 493,926 shares of the stock were exchanged, compared to its average volume of 657,199. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The stock's fifty day moving average is $141.34 and its 200 day moving average is $144.87. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period in the prior year, the business posted $0.23 earnings per share. Repligen's revenue for the quarter was up 9.7% on a year-over-year basis. Sell-side analysts predict that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.